XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating Expenses:        
Research and development $ 2,542 $ 3,380 $ 8,384 $ 9,721
General and administrative 2,794 2,584 9,076 9,962
Total operating expenses 5,336 5,964 17,460 19,683
Operating loss (5,336) (5,964) (17,460) (19,683)
Other income (expense):        
Investment income, net 451 714 1,533 2,053
Other expense, net (45) (11) (246) (175)
Total other income 406 703 1,287 1,878
Net loss before benefit from income taxes and noncontrolling interests (4,930) (5,261) (16,173) (17,805)
Benefit from income taxes 0 0 (798) (2,330)
Net loss (4,930) (5,261) (15,375) (15,475)
Less - net income (loss) attributable to noncontrolling interests 0 0 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (4,930) $ (5,261) $ (15,375) $ (15,475)
Basic and diluted loss per share        
Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) $ (0.59) $ (0.65) $ (1.85) $ (1.92)
Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) $ (0.59) $ (0.65) $ (1.85) $ (1.92)
Weighted average common shares outstanding        
Basic shares (in shares) 8,321 8,141 8,307 8,050
Diluted shares (in shares) 8,321 8,141 8,307 8,050